A Phase 2 Study of BB102 in Patients With Hepatocellular Carcinoma

Summary

This is a Phase 2 study to evaluate the efficacy and safety of BB102, a highly selective and potent FGFR4 inhibitor, as monotherapy in subjects with advanced or unresectable FGF19-overexpressing hepatocellular carcinoma. This study has two phase: dose escalation phase and expansion phase.

Timeline

Start

2025-12

Primary completion

2027-06

Completion

2028-06

Drugs

Indications